🧠 This Week in Neuroscience: Game-Changing Advances You Need to Know!
In this week’s Neuroscience Updates, we cover the latest developments shaping the future of brain health and neurotherapeutics, from billion-dollar biotech deals to breakthrough CNS therapies.
Key updates include:
🔬 J&J adds CAPLYTA® via Intra-Cellular Therapies acquisition
🧠 GSK partners with ABL Bio to improve brain drug delivery in a $2.5B deal
⚡ Biogen’s tau-targeting Alzheimer’s therapy receives FDA Fast Track
👧 Teva’s AJOVY moves toward pediatric migraine approval
❌ Genentech’s high-dose Ocrevus shows no added benefit over standard dose
🧪 Cerevance’s Parkinson’s drug shows promise without dopaminergic side effects
😴 Axsome eyes MDD subgroup with excessive daytime sleepiness for next trial
⚠️ EMA halts Sarepta trials after patient death linked to liver failure
🎯 CyberKnife shows high precision in CNS tumor treatment
📲 Tonix debuts digital migraine platform for integrated care
📢 Stay Ahead in Neuroscience Research!
✅ Like, share, and subscribe for weekly updates on Neuroscience
#Neuroscience #BiotechNews #NeuroInnovation #Neurodegeneration #BrainHealth #CNS #ClinicalTrials #PharmaNews #Alzheimers #Parkinsons #Migraine #MDD #MentalHealth #HealthcareInnovation